Skip to main content
SpringerLink
Log in

Infant ALL

  • Chapter
  • First Online:
Pediatric Acute Lymphoblastic Leukemia

  • 1002 Accesses

Abstract

Acute lymphoblastic leukemia (ALL) in infants (<1 year old) accounts for less than 5% of childhood ALL, but demonstrate as very aggressive form of ALL with KMT2A gene rearrangement (MLL-r ALL) in 70–80% of the patients. Outcome of infants with MLL-r ALL is poor with <50% event-free survival rate even with intensive chemotherapy with or without hematopoietic stem cell transplantation. Introduction of novel therapies through international collaboration is necessary for further improvement in outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2017;92:3793.

    Google Scholar 

  2. Tomizawa D. Recent progress in the treatment of infant acute lymphoblastic leukemia. Pediatr Int. 2015;57(5):811–9.

    Article  CAS  PubMed  Google Scholar 

  3. Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sakaki H, Kanegane H, Nomura K, Goi K, Sugita K, Miura M, et al. Early lineage switch in an infant acute lymphoblastic leukemia. Int J Hematol. 2009;90(5):653–5.

    Article  PubMed  Google Scholar 

  5. Pieters R, Schrappe M, de Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–50.

    Article  CAS  PubMed  Google Scholar 

  6. Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood. 2006;107(12):4663–5.

    Article  CAS  PubMed  Google Scholar 

  7. Moorman AV, Pieters R, Dreyer ZE, Heerema NA, Carroll AJ, Hunger SP, et al. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. Leukemia. 2014;28(2):428–30.

    Article  PubMed  CAS  Google Scholar 

  8. Dördelmann M, Reiter A, Borkhardt A, Ludwig WD, Götz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(4):1209–17.

    Article  PubMed  Google Scholar 

  9. Van der Velden VHJ, Corral L, Valsecchi MG, Jansen MWJC, Cazzaniga G, Schrappe M, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23(6):1073–9.

    Article  PubMed  CAS  Google Scholar 

  10. Jansen MWJC, Corral L, Van der Velden VHJ, Panzer-Grümayer R, Schrappe M, Schrauder A, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia. 2007;21(4):633–41.

    Article  CAS  PubMed  Google Scholar 

  11. Pieters R, Boer den ML, Durian M, Janka G, Schmiegelow K, Kaspers GJL, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants. Leukemia. 1998;12(9):1344–8.

    Article  CAS  PubMed  Google Scholar 

  12. Pieters R, de Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol; results from an International Phase III Randomised Study. J Clin Oncol. 2019;37(25):2246–56.

    Article  PubMed  Google Scholar 

  13. Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E, et al. Dosing anticancer drugs in infants: Current approach and recommendations from the Children“s Oncology Group”s Chemotherapy Standardization Task Force. Pediatr Blood Cancer. 2017;14(9):e26636.

    Article  Google Scholar 

  14. Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359(9321):1909–15.

    Article  PubMed  Google Scholar 

  15. Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol. 2011;29(2):214–22.

    Article  CAS  PubMed  Google Scholar 

  16. Mann G, Attarbaschi A, Schrappe M, de Lorenzo P, Peters C, Hann I, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010;116(15):2644–50.

    Article  CAS  PubMed  Google Scholar 

  17. Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol. 2002;118(4):999–1010.

    Article  CAS  PubMed  Google Scholar 

  18. Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood. 2004;104(12):3527–34.

    Article  CAS  PubMed  Google Scholar 

  19. Koh K, Tomizawa D, Moriya Saito A, Watanabe T, Miyamura T, Hirayama M, et al. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia. 2015;29(2):290–6.

    Article  CAS  PubMed  Google Scholar 

  20. Kato M, Hasegawa D, Koh K, Kato K, Takita J, Inagaki J, et al. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation. Br J Haematol. 2015;168(4):564–70.

    Article  PubMed  Google Scholar 

  21. Kawashima N, Ikoma M, Sekiya Y, Narita A, Yoshida N, Matsumoto K, et al. Successful treatment of pulmonary hypertension with beraprost and sildenafil after cord blood transplantation for infantile leukemia. Int J Hematol. 2013;97(1):147–50.

    Article  CAS  PubMed  Google Scholar 

  22. Stumpel DJPM, Schneider P, Pieters R, Stam RW. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer. 2015;51(14):2008–21.

    Article  CAS  PubMed  Google Scholar 

  23. Armstrong SA, Staunton JE, Silverman LB, Pieters R, Boer Den ML, Minden MD, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41–7.

    Article  CAS  PubMed  Google Scholar 

  24. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, Boer Den ML, Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2007;110(7):2774–5.

    Article  CAS  PubMed  Google Scholar 

  25. Zwaan CM, Söderhäll S, Brethon B, Luciani M, Rizzari C, Stam RW, et al. A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. Br J Haematol. 2018;4:263.

    Google Scholar 

  26. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823–33.

    Article  CAS  PubMed  Google Scholar 

  28. Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131(24):2661–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 2015;13(12):2715–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128(10):1382–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Stackelberg von A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381–9.

    Article  Google Scholar 

  32. Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2018;14:e205.

    Google Scholar 

  33. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013.

    Article  PubMed  Google Scholar 

  35. Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Zoghbi A, Stadt Zur U, Winkler B, Müller I, Escherich G. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatr Blood Cancer. 2017;95(6):e26594.

    Article  CAS  Google Scholar 

  37. van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, de Lorenzo P, et al. Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. Haematologica. 2016;101(3):e95–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Tomizawa D, Koh K, Hirayama M, Miyamura T, Hatanaka M, Saikawa Y, et al. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group. Pediatr Blood Cancer. 2009;52(7):808–13.

    Article  PubMed  Google Scholar 

  39. Driessen EMC, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30(5):1184–7.

    Article  CAS  PubMed  Google Scholar 

  40. Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S, et al. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children’s Oncology Group P9407. Pediatr Blood Cancer. 2012;59(5):834–9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Tomizawa D, Koh K, Sato T, Kinukawa N, Isoyama K, Kosaka Y, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007;21(11):2258–63.

    Article  CAS  PubMed  Google Scholar 

  42. Gandemer V, Bonneau J, Oudin C, Berbis J, Bertrand Y, Tabone M-D, et al. Late effects in survivors of infantile acute leukemia: a study of the L.E.A program. Blood Cancer J. 2017;7(1):e518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Geerlinks AV, Issekutz T, Wahlstrom JT, Sullivan KE, Cowan MJ, Dvorak CC, et al. Severe, persistent, and fatal T-cell immunodeficiency following therapy for infantile leukemia. Pediatr Blood Cancer. 2016;63(11):2046–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Leukemia and Lymphoma, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan

    Daisuke Tomizawa

Authors
  1. Daisuke Tomizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daisuke Tomizawa .

Editor information

Editors and Affiliations

  1. Department of Transplantation and Cell Therapy, Children’s Cancer, Center National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan

    Motohiro Kato

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tomizawa, D. (2020). Infant ALL. In: Kato, M. (eds) Pediatric Acute Lymphoblastic Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-15-0548-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0548-5_9

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0547-8

  • Online ISBN: 978-981-15-0548-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation